Physician profile
Melanie M Smith
NPI 1659317410
$8,278.19
in general payments reported to CMS, 2019-2025
41 companies · $1,360 in 2025
The $1,360 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,906 · 2020: $639 · 2021: $352 · 2022: $1,165 · 2023: $1,442 · 2024: $1,414 · 2025: $1,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,216.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,606.06 | 2019-2025 | Vraylar, Linzess, Ubrelvy |
| Glaxosmithkline, LLC. | $896.66 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $780.64 | 2019-2025 | |
| Lilly USA, LLC | $753.72 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $633.14 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $396.83 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Allergan, INC. | $382.68 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $373.45 | 2019-2025 | Belsomra, Steglatro, Januvia |
| Amgen INC. | $255.28 | 2019-2025 | Evenity |
| Tetraphase Pharmaceuticals, INC. | $225.00 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.63 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $195.89 | 2019-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $138.44 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $130.91 | 2022 | |
| Ethicon US, LLC | $126.29 | 2019 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $124.91 | 2023-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $111.71 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $90.33 | 2024-2025 | Gemtesa |
| Daiichi Sankyo INC. | $77.97 | 2020-2023 | Injectafer |
| Astellas Pharma US INC | $76.78 | 2022-2025 | Veozah |
| Axsome Therapeutics, INC. | $56.85 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $53.02 | 2023 | |
| Phathom Pharmaceuticals, INC. | $49.77 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $49.60 | 2019-2025 | |
| Exact Sciences Corporation | $49.21 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Itamar Medical INC | $47.66 | 2024-2025 | Watchpatone |
| Recor Medical INC | $46.25 | 2024-2025 | Paradise Renal Denervation System, Paradise Ultrasound Renal Denervation System |
| Amarin Pharma, INC. | $43.18 | 2019-2020 | |
| Lundbeck LLC | $40.23 | 2025 | Rexulti |
| Kci USA, INC. | $37.99 | 2023 | 3m Cavilon |
| Corcept Therapeutics | $28.24 | 2025 | Korlym |
| Biohaven Pharmaceuticals, INC. | $26.74 | 2021 | |
| Vanda Pharmaceuticals INC. | $24.72 | 2025 | Fanapt |
| Kowa Pharmaceuticals America, INC. | $23.53 | 2020-2022 | |
| Dexcom, INC. | $20.09 | 2024 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $19.88 | 2023 | Nocdurna, Xyosted, Tlando |
| Shield Therapeutics INC | $15.52 | 2025 | |
| Idorsia Pharmaceuticals US INC | $14.41 | 2023 | Quviviq |
| Axonics, INC. | $14.28 | 2022 | |
| Pacira Therapeutics, INC. | $13.49 | 2019 | |
| Sanofi Pasteur INC. | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.